SPECT/CT Streamlines Workflow and Provides Higher Resolution-to-Dose Ratios

An innovative single photon emission computed tomography/computed tomography (SPECT/CT) system helps improve clinical efficiency by streamlining workflow so that the user will receive the benefits of CT without the obstacles--offering the potential for fewer artifacts and higher resolution-to-dose ratios. Clinical advantages also include registration confidence because, in many cases, the table does not move between SPECT and CT studies.

The new BrightView XCT, developed by Philips Healthcare (Amsterdam, The Netherlands), is designed entirely for nuclear medicine, combining SPECT and CT in innovative ways to take full advantage of both without compromising either. Philips BrightView XCT uniquely integrates BrightView SPECT in a coplanar design with advanced Philips flat-detector X-ray CT technology.

The new NM Applications Portfolio allows the integration of Nuclear Medicine applications (SPECT and positron emission tomography [PET]) with CT on the Extended Brilliance Workspace. It provides a common analysis and viewing environment that is intuitive and easy to use. The ability to access, view, and analyze multi-modality studies side by side on the same platform can help improve diagnostic confidence and facilitate patient management, while simplifying workflow.

The SPECT NM Application Suite provides automated cardiac processing and reorientation, Instill-Motion correction, and state-of-the-art reconstruction software, advanced cardiac quantification software, and a comprehensive library of organ-specific analysis tools devised for general nuclear medicine applications.

The PET NM Application Suite features advanced visualization and analysis tools, and clinical applications dedicated for oncology, cardiology, and neurology. The new Tumor Tracking tool dedicated for PET/CT applications in oncology, allows physicians to monitor tumor progression, and therapy follow-up using sequential PET or PET/CT scans. It generates graphs that help physicians to track tumor volume and tumor metabolic activity changes over time.

The commercial availability of the new tumor tracking application is pending 510K U.S. Food and Drug Administration (FDA) clearance.


Related Links:
Philips Healthcare